# ğŸ“Š Prostate Cancer Survival Analysis  

## ğŸ“Œ Project Overview  
This project predicts **7-year survival outcomes** for prostate cancer patients using logistic regression models.  
The dataset contains **patient demographics, tumor characteristics, PSA levels, Gleason scores, symptoms, therapies, and staging variables**.  

This project contains:  
- **Data preparation** (cleaning, encoding, feature engineering, selection)  
- **Multiple logistic regression strategies** (forward stepwise, full model, AIC stepwise)  
- **Interpretation via odds ratios**  
- **Performance evaluation** using confusion matrices and classification reports  

---

## ğŸ“‚ Dataset  

**Final split (post-cleaning):**  
- Train: `(5929, 57)`  
- Test: `(2541, 57)`  

**Target variable:** `survival_7_years`  
- `1` = survived beyond 7 years  
- `0` = did not survive  

**Predictors:**  
- **Demographics** â€“ Age_Group, Race, BMI_Grouped  
- **Clinical Markers** â€“ PSA_diagnosis, tumor_1_year, stage  
- **Pathology** â€“ gleason_score_grouped, t_score, n_score, m_score  
- **Therapies** â€“ rd_thrpy, brch_thrpy, multi_thrpy, cry_thrpy, chm_thrpy, h_thrpy  
- **Symptoms** â€“ U05, P01, P02, P03, S10, O09, O10, O08, O01  

---

## âš™ï¸ Methodology  

### 1. Data Preparation  
- **Cleaning**  
  - Records with missing values were dropped after careful analysis.  
  - To minimize patient loss, uninformative variables were first removed using **correlation filtering** and **chi-square tests**.  
  - Since this is **clinical data**, imputing could distort medically significant patterns.  
  - Final dataset reduced from ~15k to ~8.5k patients.  

- **Type Conversion**  
  - Converted numeric variables into **categorical groups** (e.g., Age bins, Gleason groups).  
  - Encoded categorical variables into **binary indicators** (e.g., therapy received = 1/0).  

- **Feature Engineering**  
  - **Age Categories:** <60 = 1, 60â€“70 = 2, 70â€“80 = 3, 80â€“90 = 4, >90 = 5  
  - **BMI Calculation:**  
    \[
    BMI = 0.45455 \times \frac{\text{weight}}{(0.0254 \times \text{height})^2}
    \]  
    Classified as Normal (<25), Overweight (25â€“30), Obese (>30).  
  - **High-Risk Indicator:** Stage III/IV + Gleason â‰¥7 + PSA â‰¥10.  
  - **Symptom Encoding:** Converted each code into binary flags (U05, P01, P02, P03, S10, O09).  

- **Feature Selection**  
  - Correlation filtering dropped collinear tumor/PSA features.  
  - Chi-square tests removed weak predictors (e.g., previous_cancer, h_thrpy).  
  - Stepwise AIC selection reduced predictors from **57 to 13 final variables**:  
    ```
    n_score, gleason_score_grouped, tumor_1_year, m_score, rd_thrpy,
    Age_Group, U05, brch_thrpy, S10, multi_thrpy, O09, smoker, race
    ```  

---

### 2. Exploratory Analysis  
- **Univariate Analysis:** Distributions of age, PSA, Gleason, tumor stages.  
- **Bivariate Analysis:** Compared therapies, race, smoking vs. survival outcome.  
- **Correlation Analysis:** Checked collinearity among continuous features.  
- **Chi-square Tests:** Dropped non-significant categorical predictors.  

---

### 3. Model Development  
- **Forward Stepwise Logistic Regression** â€“ incremental variable selection.  
- **Full Logistic Regression (57 predictors)** â€“ broad baseline model.  
- **Final Stepwise AIC Model (13 predictors)** â€“ optimized balance of fit and simplicity.  

---

### 4. Model Evaluation  
- **Confusion Matrices** and **Classification Reports** used for performance checks.  
- Accuracy: ~64% (train and test) â†’ stable and balanced model.  

---

### 5. Interpretation  
- Regression coefficients converted to **odds ratios**.  
- Identified **key risk factors** (e.g., Gleason, N1, metastasis, smoking) and **protective factors** (e.g., radiotherapy, brachytherapy).  
- Stable predictors across models confirm clinical reliability.  

---

## ğŸ“Š Model Insights  

### ğŸ”¹ Forward Stepwise Logistic Regression  
- Prostate removal surgery â†’ 21% higher survival odds.  
- Multiple therapies â†’ 23% higher survival odds.  
- Age 60â€“70 â†’ 34% lower survival odds.  
- Age >90 â†’ 25% lower survival odds.  
- Non-obese patients â†’ 12% higher survival odds.  
- Not high-risk patients â†’ 33.5% higher survival odds.  

---

### ğŸ”¹ Full Logistic Regression (57 predictors)  
- Symptom counts (1â€“6) â†’ 50â€“110% higher survival odds.  
- Advanced T-stages (T3â€“T4) â†’ 40â€“60% worse outcomes.  
- N1 lymph nodes â†’ 59% lower survival odds.  
- Gleason 7â€“10 â†’ 28â€“50% lower survival odds.  
- Metastasis (M1a, M1b, M1c) â†’ strongly adverse, worst for **M1b (56% lower odds)**.  
- Radiotherapy â†’ 28% better survival odds.  
- Brachytherapy â†’ 14% better survival odds.  
- Age â‰¤60 â†’ 39% lower survival odds; Age 80â€“90 â†’ 22% lower.  
- Smokers â†’ 32% higher odds of death.  
- Race 1.0 â†’ 25% lower survival odds.  

---

### ğŸ”¹ Final Stepwise AIC Model (13 predictors)  
- N1 lymph nodes â†’ 63% lower survival odds.  
- Gleason scores: Group 2 â†“16%, Group 3 â†“29%, Group 4 â†“49%.  
- Metastasis: M1a â†“55%, M1b â†“76%, M1c â†“58%.  
- Tumor size at 1 year â†’ each unit â†‘ â†’ 0.7% lower odds.  
- Radiotherapy â†’ 28% better survival odds.  
- Brachytherapy â†’ 17% better survival odds.  
- Multi-therapy â†’ 16% better survival odds.  
- U05 symptom â†’ 30% lower survival odds.  
- S10 symptom â†’ 31% lower survival odds.  
- O09 symptom â†’ 60% lower survival odds.  
- Age â‰¤60 â†’ 42% lower survival odds.  
- Age 80â€“90 â†’ 22% lower survival odds.  
- Smokers â†’ 32% higher odds of death.  
- Race 1.0 â†’ 25% lower survival odds.  

---

## ğŸ“ˆ Model Performance  

| Dataset | Accuracy | Precision (0/1) | Recall (0/1) | F1-score (0/1) |  
|---------|----------|------------------|--------------|----------------|  
| **Train** | 64.2% | 0.66 / 0.63 | 0.64 / 0.65 | 0.65 / 0.64 |  
| **Test**  | 63.9% | 0.66 / 0.62 | 0.63 / 0.65 | 0.64 / 0.64 |  

- Balanced results across both classes.  
- Consistent trainâ€“test â†’ no major overfitting.  

---

## ğŸ“Œ Key Takeaways  
- **High-risk predictors:** N1 lymph nodes, higher Gleason scores, metastasis (M1b worst), smoking.  
- **Protective therapies:** Radiotherapy, brachytherapy, and multi-therapy improve survival.  
- **Demographics:** Patients â‰¤60 and 80â€“90 years had worse outcomes.  
- **Consistency:** N1, Gleason, metastasis, radiotherapy, and smoking appear in all models.  

